Modeling study: metformin timing and feeding in the liver circadian clock
In a mathematical model of the liver circadian clock, metformin given during the rising phase of CLOCK-BMAL1 had favorable effects on the clock and anti-aging outcomes, while a fed-like state was unfavorable and fasting beneficial. [1]
Automatic summary · not editorially reviewed
The key findings
The study extended a mathematical model of the liver circadian clock to include metformin regulation and ran numerical simulations. [1]
Metformin during the increasing phase of CLOCK-BMAL1 concentration showed positive clock effects and effective anti-aging properties in the model. [1]
A fed-like state was not conducive to anti-aging, whereas fasting was beneficial in the simulations. [1]
The source at a glance
- Study type / format
- Systems modeling study with numerical simulations (abstract)
- Population / context
- Simulated liver circadian clock system with metformin regulation; no human or animal population reported.
- Summary based on
- Study abstract
- Original publication
- March 20, 2026
Model of liver clock and metformin
The authors extended a mathematical model of the liver circadian clock to include metformin regulation and ran numerical simulations. They compared different dosing times and feeding conditions. The abstract does not report human participants, animals or measured outcomes; the results come from simulations of this model.
Supporting source [1]
Dosing time and feeding in simulations
Metformin at different times had distinct effects on the circadian clock and on anti-aging outcomes. Administration during the increasing phase of CLOCK-BMAL1 concentration showed positive effects on the clock and effective anti-aging properties. For feeding, a fed-like state was not conducive to anti-aging, whereas fasting was beneficial. These are model predictions, not demonstrated effects in people.
Supporting source [1]
Scope of the abstract findings
The authors conclude that dosing time and feeding style matter for optimizing metformin efficacy and mention potential pharmacological applications in anti-aging therapy. The abstract does not specify dosages, simulation parameters, validation against data or safety outcomes. It was reviewed only as an abstract; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Results come from a mathematical model and numerical simulations, with no reported human or animal data, dosages, validation or safety outcomes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhang M, Li Y. · europepmc.org · March 20, 2026